• NMDA for Excitotoxicity Assay Design

  2026-09-05

  NMDA (N-Methyl-D-aspartic acid) provides a direct, controllable trigger for receptor-mediated calcium loading and excitotoxic injury. This practical workflow connects concentration scouting with ferroptosis-aware readouts for retinal ganglion cell and neurodegenerative disease models.

• Aneugen Mechanisms Revealed by Flow Cytometry

  2026-09-04

  Bernacki and colleagues developed a tiered assay that combines DNA-damage biomarkers, Taxol-associated fluorescence, phospho-histone H3, Ki-67, clustering, and machine learning to distinguish major aneugenic mechanisms. The workflow provides a mechanistic complement to micronucleus testing by separating tubulin stabilization, tubulin destabilization, and mitotic kinase inhibition in TK6 cells.

• Amikacin disulfate: Mechanism Study Workflows

  2026-09-04

  Amikacin disulfate supports more than routine antibacterial screening: it can connect 16S rRNA-centered mechanism studies with orthogonal protein-binding and activity assays. This workflow-driven guide shows how to prepare the compound, validate assay signals, investigate lysozyme complexation, and troubleshoot instability or misleading readouts.

• Annexin V-Cy5: Separating Apoptosis from Lysosomal Stress

  2026-09-03

  In zebrafish microglia, mestranol can impair lysosomal digestion without increasing neuronal apoptosis. This thought-leadership guide explains how Annexin V-Cy5 apoptosis detection can serve as a mechanistic checkpoint, helping translational researchers distinguish phosphatidylserine exposure and true cell death from cargo accumulation, altered lysosomal function, and imaging artifacts.

• Nicotinamide Riboside Chloride in RGC Research

  2026-09-03

  Nicotinamide Riboside Chloride (NIAGEN) provides a practical way to test NAD+ metabolism in chemically defined retinal ganglion cell models. This article connects the compound’s metabolic applications with an efficient iPSC-to-RGC workflow while separating established evidence from proposed experimental extensions.

• Targeted Amikacin Delivery into Mycobacterial Granulomas

  2026-09-02

  The reference study developed a cell-based strategy to transport fluorescently labeled amikacin into Mycobacterium avium granulomas in infected mice. Its central contribution is a proof of targeted delivery using primed dendritic cells, while preserving measurable antimycobacterial activity and avoiding detectable increases in selected inflammatory markers.

• Cy3 Goat Anti-Human IgG (H+L) Antibody Workflow

  2026-09-02

  Build sensitive human IgG detection workflows for immunofluorescence, tissue imaging, flow cytometry, and ELISA with a Cy3-conjugated secondary antibody. Practical controls, optimization ranges, and troubleshooting guidance help connect antibody-binding assays with translational orthopoxvirus research without confusing detection with neutralization.

• Cy3 Goat Anti-Human IgG (H+L) Antibody Workflow

  2026-09-01

  Build sensitive human-IgG detection workflows for immunofluorescence, tissue imaging, flow cytometry, and fluorescent ELISA with a Cy3 conjugated secondary antibody. This guide also explains how to translate antibody-characterization insights from orthopoxvirus research into better assay controls without confusing a detection reagent with an antiviral therapeutic.

• Inflammation in Ischemic Stroke: Biomarkers to Treatment

  2026-09-01

  The 2025 Frontiers in Immunology review by Xiao et al. integrates inflammatory mechanisms, biomarker applications, and treatment research in ischemic stroke. Its main value is a time- and compartment-aware framework that connects blood–brain barrier disruption, central and peripheral immunity, diagnostic interpretation, and therapeutic development while emphasizing the limits of current evidence.

• Hydrazide VEGFR-2 Inhibitors: SA7 and Antiangiogenesis

  2026-08-31

  A ChemistrySelect study designed and evaluated 53 hydrazide-based derivatives as VEGFR-2-directed anticancer candidates. SA7 showed low-micromolar cytotoxicity, VEGFR-2 inhibition comparable to Sorafenib, suppression of endothelial tube formation, and stronger HCT116 xenograft control than irinotecan, supporting hydrazide scaffolds as useful starting points for antiangiogenic drug discovery.

• Salvianolic acid B: Reliable Assay Workflows

  2026-08-31

  This scenario-driven guide shows how Salvianolic acid B (SKU N1806) can support reproducible viability, proliferation, and pulmonary fibrosis research assays. It connects LH2-associated collagen remodeling evidence with practical guidance on controls, solubility, interpretation, and research-grade product selection.

• Annexin V-Cy5 Apoptosis in Lysosomal Stress

  2026-08-30

  A mechanistic and translational guide to using Annexin V-Cy5 apoptosis detection to distinguish phosphatidylserine exposure from lysosomal dysfunction in microglia, with practical recommendations for zebrafish, flow cytometry, and fluorescence microscopy workflows.

• Cy3 Goat Anti-Human IgG (H+L) Antibody

  2026-08-29

  A scenario-based laboratory guide to using Cy3 Goat Anti-Human IgG (H+L) Antibody, SKU K1208, in immunofluorescence, flow cytometry, immunohistochemistry, and ELISA workflows. It explains compatibility, controls, storage, signal interpretation, and vendor-selection criteria without treating fluorescence as a direct substitute for viability measurements.

• L-Ornithine and the Liver–Brain Axis

  2026-08-28

  L-Ornithine is more than a urea cycle intermediate: it is a controllable metabolic probe for testing how hepatic nitrogen handling may influence astrocyte energy metabolism. This thought-leadership article translates recent realgar-toxicity findings into a practical framework for liver–brain axis research, covering mechanistic rationale, assay design, reagent selection, translational boundaries, and the next experiments needed to distinguish correlation from causality.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide

  2026-08-28

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, IHC, flow cytometry, and fluorescence-based ELISA workflows. It should not be selected for non-goat primary antibodies, non-IgG targets, or experiments requiring unverified cross-species reactivity.

8115 records 1/541 page Next 12345 下5页 Last page